ZBIO Zenas Biopharma Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZBIO

Price (delayed)

$29.63

Market cap

$1.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.62

Enterprise value

$2.03B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19
Highlights
The quick ratio has soared by 90% YoY but it has contracted by 17% from the previous quarter
Zenas Biopharma's equity has decreased by 26% QoQ but it has increased by 3.1% YoY
ZBIO's EPS has dropped by 197% year-on-year and by 6% since the previous quarter
Zenas Biopharma's net income has plunged by 174% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://zenasbio.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of ZBIO

ZBIO stock price

How has the Zenas Biopharma stock price performed over time
Intraday
-10.35%
1 week
-8.32%
1 month
-8.24%
1 year
56.28%
YTD
-18.4%
QTD
16.75%

Financial performance

How have Zenas Biopharma's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$475.57M
Net income
-$484.38M
Gross margin
100%
Net margin
-48,438.4%
Zenas Biopharma's net income has plunged by 174% YoY and by 14% from the previous quarter
The company's operating income has shrunk by 151% YoY and by 12% QoQ
The gross profit has dropped by 93% year-on-year
The revenue has plunged by 93% YoY

Price vs fundamentals

How does ZBIO's price correlate with its fundamentals

Growth

What is Zenas Biopharma's growth rate over time

Valuation

What is Zenas Biopharma stock price valuation
P/E
N/A
P/B
7.57
P/S
1,870.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,032.47
ZBIO's EPS has dropped by 197% year-on-year and by 6% since the previous quarter
The P/B is 48% more than the last 4 quarters average of 5.7
Zenas Biopharma's equity has decreased by 26% QoQ but it has increased by 3.1% YoY
The revenue has plunged by 93% YoY

Efficiency

How efficient is Zenas Biopharma business performance
ZBIO's ROA has dropped by 78% year-on-year but it is up by 8% since the previous quarter
ZBIO's return on invested capital has surged by 53% year-on-year and by 27% since the previous quarter
The ROE has decreased by 13% QoQ

Dividends

What is ZBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZBIO.

Financial health

How did Zenas Biopharma financials performed over time
Zenas Biopharma's total assets is 54% more than its total liabilities
Zenas Biopharma's total assets has soared by 139% YoY but it has decreased by 6% from the previous quarter
The quick ratio has soared by 90% YoY but it has contracted by 17% from the previous quarter
ZBIO's debt is 21% greater than its equity
The company's debt to equity has surged by 53% QoQ
Zenas Biopharma's equity has decreased by 26% QoQ but it has increased by 3.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.